Pfizer’s CEO has warned that Germany’s proposed drug-pricing policies could put planned pharmaceutical investment at risk. The warning follows broader concern from global drugmakers over pricing predictability in European markets.
This is not only a Germany story. It reflects a wider conflict between governments trying to control healthcare costs and pharmaceutical companies seeking predictable returns on R&D and manufacturing investment.
The investment question is becoming as important as the pricing question.
If companies see lower pricing visibility, they may delay or reduce new production, research or supply-chain projects. For Europe, the risk is that aggressive cost control could weaken its ability to attract high-value pharmaceutical manufacturing.
For the global pharma supply chain, pricing policy is now part of industrial policy.
